💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Galapagos launches early-stage study of GLPG3221 in cystic fibrosis, earns $10M milestone from AbbVie

Published 11/21/2017, 04:17 PM
© Reuters.  Galapagos launches early-stage study of GLPG3221 in cystic fibrosis, earns $10M milestone from AbbVie
GLPG
-
ABBV
-
  • Galapagos NV (NASDAQ:GLPG) initiates a Phase 1 clinical trial assessing C2 corrector GLPG3221 for the treatment of cystic fibrosis (CF). The action triggers a $10M milestone payment from collaboration partner AbbVie (NYSE:ABBV).
  • The study will evaluate the safety, tolerability and pharmacokinetics of GLPG3221 in healthy volunteers. Topline data will be submitted for presentation at a future medical conference.
  • The company and AbbVie are developing a triplet therapy for CF, of which GLPG3221 is the second C2 corrector, chemically distinct from the first C2 corrector. The first triple combo study in patients will commence this quarter.
  • A C2 corrector is a CFTR corrector molecule that improves the trafficking of the CFTR protein and enhances its stability thereby enabling the functional expression of CFTR at the cell surface.
  • Now read: New Div On The Block Quarterly Earnings Round-Up II: Part 2


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.